Four University of Toronto (U of T) professors who have commercialization projects in various stages with MaRS Innovation were named to the university's list of Inventors of the Year.
“The Inventor of the Year Award is meant to recognize inventions that have the potential to improve our quality of life,” said Professor Paul Young, vice-president (research and innovation) and a member of MaRS Innovation's Board of Directors. “The winning inventions represent the very best of innovation at U of T, and on ...
MaRS Innovation's (MI) Lyssa Neel, co-director of the UTEST program and project manager, has been selected to represent MI's ICT start-up companies at the TechWomen Canada program in San Francisco, which runs May 13 to 16, 2013.
The announcement was covered in TechVibes:
TechWomen Canada is run by the Canadian Consulate and is focused on providing Canadian women leaders in the ICT sector an opportunity to expand both professional and business networks in Silicon Valley. (more…)
Every six weeks, MaRS Innovation's marketing and communications manager writes a guest post for the MaRS Discovery District blog profiling MI's activities or one of our start-up companies. You can read the original post on the MaRS blog.
Nearly 14,000 delegates—representing over 1,100 biotechnology companies, academic institutions, state biotechnology centres and related organizations across the United States and more than 60 countries—attended the 2013 BIO International Convention from April 22 to 26, 2013.
The event drew biotechnologists, pharmaceutical industry executives and life sciences researchers, ...
A $4-million public-private partnership will promote research innovation involving three academic commercialization centres in Canada
CHICAGO, Illinois – April 22, 2013 – Merck Canada will be announcing today at the BIO International Convention that it is reinforcing its commitment to the Canadian life sciences research innovation sector.
Merck will provide $4 million in funding to the Institute for Research in Immunology and Cancer – Commercialization of Research (IRICoR) for future corridor projects developed in collaboration with two other Canadian Centres of Excellence for ...
Dr. Kamran Khan, founder of BioDiaspora and an infectious disease physician and scientist at St. Michael's Hospital, is among the experts studying the emergence of the H7N9 bird flu outbreak in China.
Jennifer Yang interviewed Khan in today's Toronto Star about the likelihood of the disease being easily transmitted from human to human or arriving in Canada, as SARS did in 2003.
Here's an excerpt:
“This isn’t necessarily an event that poses a significant risk to Canada, at least based on all the current ...
Government has key role to play as early-stage technology adopter says CEO Raphael Hofstein
Dr. Raphael Hofstein, president and CEO of MaRS Innovation, was quoted in Mary Theresa Bitti's National Post article, "Commercialization Conundrum: Canada must turn ideas into social and economic value," published April 3, 2013.
The article examines Canada's worsening track record in realizing commercialization gains based on the country's significant per-capita investment in R&D.
Here's an excerpt:
While Canada punches above its weight class when it comes to generating ideas — witness ...
TORONTO, ON (Feb. 19, 2013) – XLV Diagnostics Inc., a start-up company working to commercialize a faster, cheaper and better digital mammography technology, has received a $500,000 investment from FedNor.
Over 600 million women living in developing countries have inadequate access to breast screening for early cancer detection. In the developed world, many radiology departments are replacing traditional film and screen systems with digital technologies. In both cases, better digital mammography technology promises to solve logistical challenges and save money.
XLV’s solution has ...